Do analysts prefer NIOX or TSTL?

NIOX Group currently has a consensus target price of GBX 86, indicating a potential upside of 31.87%. Given NIOX Group's stronger consensus rating and higher probable upside, research analysts clearly believe NIOX Group is more favorable than Tristel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NIOX Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Tristel 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, NIOX or TSTL?

NIOX Group has higher earnings, but lower revenue than Tristel. Tristel is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NIOX Group £48.70M 5.64 £995.88M £1.64 39.77 Tristel £49.54M 3.86 £6.54M £16.24 24.48

Is NIOX or TSTL more profitable?

Tristel has a net margin of 15.88% compared to NIOX Group's net margin of 14.37%. Tristel's return on equity of 23.64% beat NIOX Group's return on equity. Company Net Margins Return on Equity Return on Assets NIOX Group 14.37% 10.14% 3.95% Tristel 15.88% 23.64% 9.89%

NIOX Group (NIOX) Competitors

GBX 65.22 +0.22 (+0.34%)

As of 09/11/2026 12:44 PM Eastern

Compare

NIOX vs. AMS, TSTL, EKF, SPEC, and CREO

Should you buy NIOX Group stock or one of its competitors? NIOX Group's main competitors and comparable companies include Advanced Medical Solutions Group (AMS), Tristel (TSTL), EKF Diagnostics (EKF), INSPECS Group (SPEC), and Creo Medical Group (CREO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does NIOX Group compare to Advanced Medical Solutions Group?

NIOX Group (LON:NIOX) and Advanced Medical Solutions Group (LON:AMS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

NIOX Group has a net margin of 14.37% compared to Advanced Medical Solutions Group's net margin of 4.35%. NIOX Group's return on equity of 10.14% beat Advanced Medical Solutions Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NIOX Group	14.37%	10.14%	3.95%
Advanced Medical Solutions Group	4.35%	3.87%	2.35%

In the previous week, NIOX Group's average media sentiment score of 0.00 equaled Advanced Medical Solutions Group'saverage media sentiment score.

Company	Overall Sentiment
NIOX Group	Neutral
Advanced Medical Solutions Group	Neutral

NIOX Group has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, Advanced Medical Solutions Group has a beta of 0.704, suggesting that its share price is 30% less volatile than the broader market.

NIOX Group presently has a consensus target price of GBX 86, suggesting a potential upside of 31.87%. Advanced Medical Solutions Group has a consensus target price of GBX 270.25, suggesting a potential downside of 3.65%. Given NIOX Group's stronger consensus rating and higher probable upside, equities research analysts clearly believe NIOX Group is more favorable than Advanced Medical Solutions Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NIOX Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Advanced Medical Solutions Group	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

7.6% of NIOX Group shares are owned by institutional investors. Comparatively, 21.5% of Advanced Medical Solutions Group shares are owned by institutional investors. 5.1% of NIOX Group shares are owned by insiders. Comparatively, 4.0% of Advanced Medical Solutions Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

NIOX Group pays an annual dividend of GBX 1.25 per share and has a dividend yield of 1.9%. Advanced Medical Solutions Group pays an annual dividend of GBX 2.68 per share and has a dividend yield of 1.0%. NIOX Group pays out 76.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Advanced Medical Solutions Group pays out 59.3% of its earnings in the form of a dividend.

NIOX Group has higher earnings, but lower revenue than Advanced Medical Solutions Group. NIOX Group is trading at a lower price-to-earnings ratio than Advanced Medical Solutions Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NIOX Group	£48.70M	5.64	£995.88M	£1.64	39.77
Advanced Medical Solutions Group	£228.94M	2.67	£11.22M	£4.52	62.06

Summary

NIOX Group beats Advanced Medical Solutions Group on 10 of the 16 factors compared between the two stocks.

How does NIOX Group compare to Tristel?

NIOX Group (LON:NIOX) and Tristel (LON:TSTL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

NIOX Group has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, Tristel has a beta of 0.344, meaning that its stock price is 66% less volatile than the broader market.

NIOX Group pays an annual dividend of GBX 1.25 per share and has a dividend yield of 1.9%. Tristel pays an annual dividend of GBX 14.20 per share and has a dividend yield of 3.6%. NIOX Group pays out 76.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Tristel pays out 87.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Tristel has a net margin of 15.88% compared to NIOX Group's net margin of 14.37%. Tristel's return on equity of 23.64% beat NIOX Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NIOX Group	14.37%	10.14%	3.95%
Tristel	15.88%	23.64%	9.89%

7.6% of NIOX Group shares are owned by institutional investors. Comparatively, 22.4% of Tristel shares are owned by institutional investors. 5.1% of NIOX Group shares are owned by insiders. Comparatively, 21.0% of Tristel shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, NIOX Group's average media sentiment score of 0.00 equaled Tristel'saverage media sentiment score.

Company	Overall Sentiment
NIOX Group	Neutral
Tristel	Neutral

NIOX Group has higher earnings, but lower revenue than Tristel. Tristel is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NIOX Group	£48.70M	5.64	£995.88M	£1.64	39.77
Tristel	£49.54M	3.86	£6.54M	£16.24	24.48

NIOX Group currently has a consensus target price of GBX 86, indicating a potential upside of 31.87%. Given NIOX Group's stronger consensus rating and higher probable upside, research analysts clearly believe NIOX Group is more favorable than Tristel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NIOX Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tristel	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

NIOX Group and Tristel tied by winning 8 of the 16 factors compared between the two stocks.

How does NIOX Group compare to EKF Diagnostics?

EKF Diagnostics (LON:EKF) and NIOX Group (LON:NIOX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

NIOX Group has a net margin of 14.37% compared to EKF Diagnostics' net margin of 4.12%. NIOX Group's return on equity of 10.14% beat EKF Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
EKF Diagnostics	4.12%	3.01%	5.27%
NIOX Group	14.37%	10.14%	3.95%

In the previous week, EKF Diagnostics' average media sentiment score of 0.00 equaled NIOX Group'saverage media sentiment score.

Company	Overall Sentiment
EKF Diagnostics	Neutral
NIOX Group	Neutral

22.2% of EKF Diagnostics shares are held by institutional investors. Comparatively, 7.6% of NIOX Group shares are held by institutional investors. 40.2% of EKF Diagnostics shares are held by company insiders. Comparatively, 5.1% of NIOX Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

EKF Diagnostics has a beta of 0.499, indicating that its stock price is 50% less volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

EKF Diagnostics currently has a consensus price target of GBX 35, indicating a potential upside of 37.54%. NIOX Group has a consensus price target of GBX 86, indicating a potential upside of 31.87%. Given EKF Diagnostics' higher possible upside, equities analysts plainly believe EKF Diagnostics is more favorable than NIOX Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EKF Diagnostics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
NIOX Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

NIOX Group has lower revenue, but higher earnings than EKF Diagnostics. NIOX Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EKF Diagnostics	£51.56M	2.11	£4.68M	£0.47	54.14
NIOX Group	£48.70M	5.64	£995.88M	£1.64	39.77

Summary

EKF Diagnostics and NIOX Group tied by winning 6 of the 12 factors compared between the two stocks.

How does NIOX Group compare to INSPECS Group?

NIOX Group (LON:NIOX) and INSPECS Group (LON:SPEC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

NIOX Group has a net margin of 14.37% compared to INSPECS Group's net margin of -2.67%. NIOX Group's return on equity of 10.14% beat INSPECS Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NIOX Group	14.37%	10.14%	3.95%
INSPECS Group	-2.67%	-6.07%	0.45%

In the previous week, INSPECS Group had 4 more articles in the media than NIOX Group. MarketBeat recorded 4 mentions for INSPECS Group and 0 mentions for NIOX Group. NIOX Group's average media sentiment score of 0.00 beat INSPECS Group's score of -0.34 indicating that NIOX Group is being referred to more favorably in the media.

Company	Overall Sentiment
NIOX Group	Neutral
INSPECS Group	Neutral

NIOX Group has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NIOX Group	£48.70M	5.64	£995.88M	£1.64	39.77
INSPECS Group	£191.70M	0.55	-£4.11M	-£9.40	N/A

7.6% of NIOX Group shares are held by institutional investors. Comparatively, 0.2% of INSPECS Group shares are held by institutional investors. 5.1% of NIOX Group shares are held by insiders. Comparatively, 19.6% of INSPECS Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

NIOX Group currently has a consensus target price of GBX 86, indicating a potential upside of 31.87%. INSPECS Group has a consensus target price of GBX 60, indicating a potential downside of 37.50%. Given NIOX Group's higher probable upside, equities analysts plainly believe NIOX Group is more favorable than INSPECS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NIOX Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
INSPECS Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

NIOX Group has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.603, suggesting that its share price is 60% more volatile than the broader market.

Summary

NIOX Group beats INSPECS Group on 10 of the 14 factors compared between the two stocks.

How does NIOX Group compare to Creo Medical Group?

NIOX Group (LON:NIOX) and Creo Medical Group (LON:CREO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

NIOX Group presently has a consensus price target of GBX 86, indicating a potential upside of 31.87%. Creo Medical Group has a consensus price target of GBX 40, indicating a potential upside of 220.00%. Given Creo Medical Group's higher probable upside, analysts clearly believe Creo Medical Group is more favorable than NIOX Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NIOX Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Creo Medical Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

NIOX Group has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NIOX Group	£48.70M	5.64	£995.88M	£1.64	39.77
Creo Medical Group	£6M	10.12	-£25.04M	£1.00	12.50

In the previous week, Creo Medical Group's average media sentiment score of 0.75 beat NIOX Group's score of 0.00 indicating that Creo Medical Group is being referred to more favorably in the news media.

Company	Overall Sentiment
NIOX Group	Neutral
Creo Medical Group	Positive

Creo Medical Group has a net margin of 88.33% compared to NIOX Group's net margin of 14.37%. NIOX Group's return on equity of 10.14% beat Creo Medical Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NIOX Group	14.37%	10.14%	3.95%
Creo Medical Group	88.33%	9.56%	-20.09%

NIOX Group has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.563854, suggesting that its share price is 56% more volatile than the broader market.

7.6% of NIOX Group shares are held by institutional investors. Comparatively, 44.1% of Creo Medical Group shares are held by institutional investors. 5.1% of NIOX Group shares are held by company insiders. Comparatively, 7.0% of Creo Medical Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

NIOX Group beats Creo Medical Group on 8 of the 15 factors compared between the two stocks.

Get NIOX Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NIOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NIOX vs. The Competition

Export

Metric	NIOX Group	Healthcare Equipment & Supplies Industry	Healthcare Sector	LON Exchange
Market Cap	£274.48M	£5.42B	£7.16B	£2.87B
Dividend Yield	2.28%	1.79%	2.56%	6.23%
P/E Ratio	39.77	24.86	274.10	366.83
Price / Sales	5.64	82.29	656.00	83,599.70
Price / Cash	11.21	32.53	77.04	27.89
Price / Book	3.62	5.97	10.33	6.33
Net Income	£995.88M	£150.14M	£3.50B	£5.89B
7 Day Performance	-3.52%	-2.83%	-3.35%	-0.69%
1 Month Performance	1.90%	-3.09%	-0.43%	0.18%
1 Year Performance	-8.14%	9.34%	19.21%	20.03%

NIOX Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NIOX NIOX Group	N/A	GBX 65.22 +0.3%	GBX 86 +31.9%	-7.4%	£274.48M	£48.70M	39.77	92	Gap Up
AMS Advanced Medical Solutions Group	N/A	GBX 281 flat	GBX 270.25 -3.8%	+35.5%	£611.45M	£228.94M	62.17	10
TSTL Tristel	N/A	GBX 411 -1.0%	N/A	+12.9%	£197.27M	£49.54M	25.31	208
EKF EKF Diagnostics	N/A	GBX 25.16 -0.6%	GBX 35 +39.1%	-12.3%	£108.18M	£51.56M	53.53	356
SPEC INSPECS Group	0.5631 of 5 stars	GBX 96 flat	GBX 60 -37.5%	N/A	£104.81M	£191.70M	N/A	1,673	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:NIOX) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NIOX Group (NIOX) Competitors

NIOX vs. AMS, TSTL, EKF, SPEC, and CREO

How does NIOX Group compare to Advanced Medical Solutions Group?

Summary

How does NIOX Group compare to Tristel?

Summary

How does NIOX Group compare to EKF Diagnostics?

Summary

How does NIOX Group compare to INSPECS Group?

Summary

How does NIOX Group compare to Creo Medical Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NIOX vs. The Competition

NIOX Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NIOX Group (NIOX) Competitors

NIOX vs. AMS, TSTL, EKF, SPEC, and CREO

How does NIOX Group compare to Advanced Medical Solutions Group?

Is NIOX or AMS more profitable?

Does the media prefer NIOX or AMS?

Which has more volatility and risk, NIOX or AMS?

Do analysts prefer NIOX or AMS?

Do insiders and institutionals have more ownership in NIOX or AMS?

Is NIOX or AMS a better dividend stock?

Which has higher earnings and valuation, NIOX or AMS?

Summary

How does NIOX Group compare to Tristel?

Which has more risk and volatility, NIOX or TSTL?

Is NIOX or TSTL a better dividend stock?

Is NIOX or TSTL more profitable?

Do insiders and institutionals have more ownership in NIOX or TSTL?

Does the media favor NIOX or TSTL?

Which has preferable earnings & valuation, NIOX or TSTL?

Do analysts prefer NIOX or TSTL?

Summary

How does NIOX Group compare to EKF Diagnostics?

Is EKF or NIOX more profitable?

Does the media prefer EKF or NIOX?

Do insiders and institutionals believe in EKF or NIOX?

Which has more risk and volatility, EKF or NIOX?

Do analysts recommend EKF or NIOX?

Which has higher valuation & earnings, EKF or NIOX?

Summary

How does NIOX Group compare to INSPECS Group?

Is NIOX or SPEC more profitable?

Does the media refer more to NIOX or SPEC?

Which has higher valuation and earnings, NIOX or SPEC?

Do institutionals & insiders believe in NIOX or SPEC?

Do analysts prefer NIOX or SPEC?

Which has more risk and volatility, NIOX or SPEC?

Summary

How does NIOX Group compare to Creo Medical Group?

Do analysts prefer NIOX or CREO?

Which has preferable earnings & valuation, NIOX or CREO?

Does the media refer more to NIOX or CREO?

Is NIOX or CREO more profitable?

Which has more volatility and risk, NIOX or CREO?

Do institutionals and insiders believe in NIOX or CREO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NIOX vs. The Competition

NIOX Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools